Obesity and diabetes: The links and common approaches

Primary Care Diabetes

Volumn 4, Issue 2, 2010, Pages 105-112

  Haslam, David ^a  

^a NONE   (United Kingdom)

Author keywords

Anti obesity drugs; Bariatric surgery; Diabesity; Diabetes; Hypoglycaemic agents; Obesity

Indexed keywords

AMPHETAMINE; ANTIOBESITY AGENT; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; RIMONABANT; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; VILDAGLIPTIN; ANTIDIABETIC AGENT;

BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DISEASE ASSOCIATION; DISEASE COURSE; GASTRIC BANDING; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCREENING; STOMACH BYPASS; WEIGHT GAIN; BARIATRIC SURGERY; COMPLICATION; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; TREATMENT OUTCOME;

EID: 77957201362     PISSN: 17519918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcd.2010.04.002     Document Type: Note

References (59)

1. S.G. Wannamethee, and A.G. Shaper Weight change and duration of overweight and obesity in the incidence of type 2 diabetes Diabetes Care 22 1999 1266 1272
2. Counterweight data, unpublished, Presented at Hazardous Waist; Men's Health Forum Conference, Savoy Place, London, 13/6/05.
3. C. Currie, J. Peters, A. Tynan, M. Evans, R. Heine, O. Bracco, Y. Zagar, and C. Poole Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study Lancet 375 February (9713) 2010 481 489
4. D. Adler, The Life and Cuisine of Elvis Presley.
5. G. Reaven Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
6. An Interview with Gerald Reaven: Syndrome X: The Risks of Insulin Resistance, http://www.cacr.ca/information-for-public/archived-issues/2000s/ 0009Reaven.pdf (accessed 3.4.10).
7. Rationale for new IDF worldwide definition of metabolic syndrome, http://www.idf.org/webdata/docs/Metabolic-syndrome-rationale.pdf (accessed 3.4.10).
8. http://www.idf.org/webdata/docs/MetS-def-update2006.pdf (accessed 3.4.10).
9. I. Lemieux, A. Pascot, C. Couillard, B. Lamarche, A. Tchernof, N. Alméras, J. Bergeron, D. Gaudet, G. Tremblay, D. Prud'homme, A. Nadeau, and J.-P. Després Hypertriglyceridemic waist, a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102 2000 179 184
10. N.V. Christou, J.S. Sampalis, and M. Liberman Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients Ann. Surg. 240 3 2004 416 424
11. C.L. Keating, J.B. Dixon, and M.L. Moodie Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modelled lifetime analysis Diabetes Care 2009
12. T. Adams, M.P.H. Richard, E. Gres, S.C. Smith, R.C. Halverson, S. Simper, W.D. Rosamond, M LaMonte, M. Antoinette, M. Stroup, and S. Hunt Long-term mortality after gastric bypass surgery NEJM 357 2007 753 761
13. L. Sjöström, K. Narbro, C.D. Sjöström, K. Karasno, B. Larsson, H. Wedel, T. Lystig, M. Sullivan, C. Bouchard, B. Carlsson, C. Bengtsson, S. Dahlgren, A. Gummesson, P. Jacobson, J. Karlsson, A. Lindroos, H. Lönroth, I. Näslund, T. Olbers, K. Stenlöf, J. Torgerson, G. gren, and L. Carlsson Effects of bariatric surgery on mortality in Swedish obese subjects NEJM 357 2007 741 752
14. L. Sjöström, A. Lindroos, M. Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, S. Dahlgren, B. Larsson, K. Narbro, C.D. Sjöström, M. Sullivan, and H. Wedel Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery NEJM 351 2004 2683 2693
15. C.-L. Eric Yen Deficiency of the intestinal enzyme acyl coa:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding Nat. Med. 2009 (advance online publication)
16. M. Deitel From bariatric to metabolic surgery in non-obese subjects: time for some caution Arq. Bras. Endocrinol. Metab. 53 no. 2 2009
17. A.L. DePaula, C.A. Macedo, N. Rassi, C.A. Machado, Schraibman, L.Q. Silva, and A. Halpern Laparoscopic treatment of type 2 diabetes mellitus for patients with body mass index less than 35 Surg. Endosc. 22 3 2008 706 716
18. 2 (LBMI) Obes. Surg. 2008 (Epub ahead of print)
19. J.B. Dixon, P.E. O'Brien, J. Playfair, L. Chapman, L.M. Schachter, S. Skinner, J. Proietto, M. Bailey, and M. Anderson Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized control trial JAMA 299 3 2008 316 323
20. J.J. Omana, S.Q. Nguyen, D. Herron, and S. Kini Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding Surg. Endosc. 2010 (Epub ahead of print)
21. R. Schouten, C.S. Rijs, N.D. Bouvy, W. Hameeteman, G.H. Koek, I.M. Janssen, and J.W. Greve A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery Ann. Surg. 251 February (2) 2010 236 243
22. K.S. Gersin, R.I. Rothstein, R.J. Rosenthal, D. Stefanidis, S.E. Deal, T.S. Kuwada, W. Laycock, G. Adrales, M. Vassiliou, S. Szomstein, S. Heller, A.M. Joyce, F. Heiss, and D. Nepomnayshy Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates Gastrointest. Endosc. 2010 (Epub ahead of print)
23. J. Rosenstock, P. Hollander, S. Chevalier, and Iranmanesh A The SERENADE trial: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naïve type 2 diabetes Diabetes Care 2008 10.2337/dc08-0386 (Published online before print)
24. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjostrom XENical in the prevention of diabetes in obese subjects (XENDOS) study Diabetes Care 27 2004 155 161
25. L. Sjöström Analysis of the XENDOS study (Xenical in the prevention of diabetes in obese subjects) Endocr. Pract. 12 January-February (Suppl. 1) 2006 31 33
26. C. Berne A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin Diabetic Med. 22 2004 612 618
27. A. Wirth Reduction of body weight and co-morbidities by orlistat: the XXL - primary health care trial Diabetes Obes. Metab. 7 January (1) 2005 21 27
28. E. Bull Obesity; orlistat Drugs Context 1 6 2004 193 232
29. W.P.T. James Lancet 356 2000 2119 2125
30. D. Rucker, R. Padwal, S.K. Li, C. Curioni, and Lau DCW Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 2007 10.1136/bmj.39385.413113.25 (online publication). N.B. Erratum on sibutramine issued 21.11.09 (Pubitemid 350273303)
31. D. Haslam Sibutramine: gone but not forgotten Pract. Diabetes Int. 27 No 3 2010 96 97
32. http://www.idf.org/webdata/docs/GGT2D%2001%20Screening%20and%20diagnosis. pdf (accessed 4.4.10).
33. S. Mayor Quarter of people with diabetes in England are undiagnosed BMJ 331 7518 2005 656
34. National Collaborating Centre for Chronic Conditions Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update) 2008 Royal College of Physicians London
35. L. Ryden, E. Standl, and M. Bartnik Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. 28 1 2007 88 136
36. Joint British Societies JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart 91 Suppl. v 2005 v1 v52
37. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 1 2009 193 203
38. National Health Service National Clinical Audit Support Programme (Diabetes) 2009 http://www.ic.nhs.GBR/services/national-clinical-audit-support- programme ncasp/diabetes/analysis (accessed 10.02.09)
39. K. Kotseva, D. Wood, and G. De Backer Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 9667 2009 929 940
40. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N. Engl. J. Med. 359 15 2008 1577 1589
41. GBR Prospective Diabetes Study (GBRPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (GBRPDS 33) Lancet 352 9131 1998 837 853
42. R. Turner, C. Cull, and R. Holman GBR Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus Ann. Intern. Med. 124 1 Pt 2 1996 136 145
43. ADVANCE Collaborative Group N. Engl. J. Med. 358 2008 2560 2572
44. A. Patel, S. MacMahon, and J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 358 24 2008 2560 2572
45. W. Duckworth, C. Abraira, and T. Moritz Glucose control and vascular complications in veterans with type 2 diabetes N. Engl. J. Med. 360 2 2009 129 139
46. GBR Prospective Diabetes Study (GBRPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (GBRPDS 34) Lancet 352 9131 1998 854 865
47. A. Fontbonne, M.A. Charles, and I. Juhan-Vague The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group Diabetes Care 19 9 1996 920 926
48. H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N. Engl. J. Med. 358 24 2008 2545 2559
49. C.J. Currie, J.R. Peters, A. Tynan, M. Evans, R.J. Heine, O.L. Bracco, and T. Zagar Poole CD Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study Lancet 375 9713 2010 481 489
50. W. Duckworth, Glycemic control and cardiovascular outcomes - the VA diabetes trial, American Diabetes Association 68th Scientific Sessions: VA Diabetes Trial Symposium, Presented 8 June 2008, Webcast available at http://www.diabetesconnect.org/storetemplate/Webcast-list.aspx?ses=874 (accessed 4.4.10), 2008.
51. D. Bonds The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340 2010 b4909
52. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 9548 2006 1696 1705
53. Sitagliptin Study 020 Group Diabetes Care 29 2006 2638 2643
54. I. Raz, Y. Chen, M. Wu, S. Hussain, K.D. Kaufman, J.M. Amatruda, R.B. Langdon, P.P. Stein, and M. Alba Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr. Med. Res. Opin. 24 February (2) 2008 537 550
55. E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, and A.J. Garber Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin Diabetes Care 30 4 2007 890 895
56. S. Del Prato Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes Int. J. Clin. Pract. Suppl. August (154) 2007 38 48 (Pubitemid 46938546)
57. J.B. Buse, D.C. Klonoff, and L.L. Nielsen Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin. Ther. 29 1 2007 139 153
58. M. Nauck, A. Frid, and K. Hermansen Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 32 1 2009 84 90
59. J. Jendle, M.A. Nauck, D. Matthews D., et al., The reduction of body weight with liraglutide, a once-daily human GLP-1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat, Presented at the 44th European Association for the Study of Diabetes Annual Meeting, Rome, Italy, 7-11 September, 2008.